Oral administration of recombinant Lactococcus lactis expressing HSP65 and tandemly repeated P277 reduces the incidence of type I diabetes in non-obese diabetic mice

PLoS ONE

Volumn 9, Issue 8, 2014, Pages

  Ma, Yanjun ^a,b   Liu, Jingjing ^b   Hou, Jing ^b   Dong, Yuankai ^b   Lu, Yong ^b   Jin, Liang ^b   Cao, Rongyue ^b   Li, Taiming ^b   Wu, Jie ^b  

^a Key Laboratory of Wildlife Evidence Technology of National Forestry and Grassland Administration   (China)

^b CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GLUCOSE; HEAT SHOCK PROTEIN 65; INTERLEUKIN 10; NISIN; PEPTIDE; PROBIOTIC AGENT; PROTEIN 6P277; UNCLASSIFIED DRUG; CHAPERONIN 60; CYTOKINE; HEAT SHOCK PROTEIN; HYBRID PROTEIN; PEPTIDE 277, HEAT SHOCK PROTEIN 60; PEPTIDE FRAGMENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL STRAIN; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GLUCOSE TOLERANCE; GLUCOSE TOLERANCE TEST; HISTOPATHOLOGY; HYPERGLYCEMIA; IMMUNIZATION; IMMUNOLOGICAL TOLERANCE; INSULIN DEPENDENT DIABETES MELLITUS; INSULITIS; LACTOCOCCUS LACTIS; LYMPHOCYTE PROLIFERATION; MORBIDITY; MOUSE; NONHUMAN; NONOBESE DIABETIC MOUSE; NUCLEOTIDE SEQUENCE; PANCREAS; PROTEIN EXPRESSION; SPLEEN CELL; T LYMPHOCYTE; VACCINATION; WESTERN BLOTTING; ANIMAL; CYTOLOGY; DIABETES MELLITUS, TYPE 1; GENETICS; HUMAN; IMMUNOLOGY; INCIDENCE; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANIMALS; CHAPERONIN 60; CYTOKINES; DIABETES MELLITUS, TYPE 1; FEMALE; HEAT-SHOCK PROTEINS; HUMANS; INCIDENCE; LACTOCOCCUS LACTIS; MICE; MICE, INBRED NOD; PEPTIDE FRAGMENTS; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES;

EID: 84929294360     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0105701     Document Type: Article

References (35)

1. Luo X, Herold KC, Miller SD (2010) Immunotherapy of type 1 diabetes: where are we and where should we be going? Immunity 32: 488-499.
2. Van Belle TL, Coppieters KT, von Herrath MG (2011) Type 1 diabetes: etiology, immunology, and therapeutic strategies. Physiol Rev 91: 79-118.
3. Petrovsky N (2010) Immunomodulation with microbial vaccines to prevent type 1 diabetes mellitus. Nat Rev Endocrinol 6: 131-138.
4. Elias D, Cohen IR (1994) Peptide therapy for diabetes in NOD mice. Lancet 343: 704-706 (Pubitemid 24087851)
5. Raz I, Ziegler AG, Linn T, Schernthaner G, Bonnici F, et al. (2014) Treatment of recent-onset type 1 diabetic patients with DiaPep277: results of double-blind, placebo-controlled, randomized phase 3 trial. Diabetes Care 37: 1392-400.
6. Liang J, Aihua Z, Yu W, Yong L, Jingjing L (2010) HSP65 serves as an immunogenic carrier for a diabetogenic peptide P277 inducing anti-inflammatory immune response in NOD mice by nasal administration. Vaccine 28: 3312-3317.
7. Portaro FC, Hayashi MA, De Arauz LJ, Palma MS, Assakura MT, et al. (2002) The Mycobacterium leprae hsp65 displays proteolytic activity. Mutagenesis studies indicate that the M. leprae hsp65 proteolytic activity is catalytically related to the HslVU protease. Biochemistry 41: 7400-7406. (Pubitemid 34602458)
8. Neirynck S, Steidler L (2006) Delivery of therapeutic proteins through Lactococcus lactis. Biotechnol Genet Eng Rev 22: 253-266.
9. Steidler L, Rottiers P (2006) Therapeutic drug delivery by genetically modified Lactococcus lactis. Ann N Y Acad Sci. 1072: 176-186. (Pubitemid 44448451)
10. Miettinen M, Vuopio-Varkila J, Varkila K (1996) Production of human tumor necrosis factor alpha, interleukin-6, and interleukin-10 is induced by lactic acid bacteria. Infect Immun 64: 5403-5405. (Pubitemid 26404010)
11. Adel-Patient K, Ah-Leung S, Creminon C, Nouaille S, Chatel JM, et al. (2005) Oral administration of recombinant Lactococcus lactis expressing bovine beta-lactoglobulin partially prevents mice from sensitization. Clin Exp Allergy 35: 539-546. (Pubitemid 40577249)
12. Steidler L, Neirynck S, Huyghebaert N, Snoeck V, Vermeire A, et al. (2003) Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10. Nat Biotechnol 21: 785-789. (Pubitemid 36791397)
13. Vandenbroucke K, de Haard H, Beirnaert E, Dreier T, Lauwereys M, et al. (2010) Orally administered L. lactis secreting an anti-TNF Nanobody demonstrate efficacy in chronic colitis. Mucosal Immunology 3: 49-56.
14. Robert S, Gysemans C, Takiishi T, Korf H, Spagnuolo I, et al. (2014) Oral delivery of Glutamic Acid Decarboxylase (GAD)-65 and IL10 by Lactococcus lactis reverses diabetes in recent-onset NOD mice. Diabetes. [Epub ahead of print]
15. Takiishi T, Korf H, Belle TV, Robert S, Grieco FA, et al. (2012) Reversal of autoimmune diabetes by restoration of antigen-specific tolerance using genetically modified Lactococcus lactis in mice. J Clin Invest 122: 1717-1725.
16. Jin L, Wang Y, Xiong Q, Chen Q, Li J, et al. (2007) Long-lasting specific antibodies against P277 induced by mucosal administration of P277 repeat sequences carried by Hsp65 in the absence of adjuvants. Vaccine 25: 2043-2050. (Pubitemid 46227676)
17. McIntyre DA, Harlander SK (1989) Genetic transformation of intact Lactococcus lactis subsp. lactis by high-voltage electroporation. Appl Environ Microbiol 55: 604-610. (Pubitemid 19085119)
18. van der Vossen JM, van der Lelie D, Venema G (1987) Isolation and characterization of Streptococcus cremoris Wg2-specific promoters. Appl Environ Microbiol 53: 2452-2457.
19. van Asseldonk M, Rutten G, Oteman M, Siezen RJ, de Vos WM, et al. (1990) Cloning of usp45, a gene encoding a secreted protein from Lactococcus lactis subsp. lactis MG1363. Gene 95: 155-160.
20. Jing H, Yong L, Haiyan L, Yanjun M, Yun X, et al. (2011) Oral administration of Lactococcus lactis delivered heat shock protein 65 attenuates atherosclerosis in low-density lipoprotein receptor-deficient mice. Vaccine 29: 4102-4109.
21. Lu Y, Ouyang K, Fang J, Zhang H, Wu G, et al. (2009) Improved efficacy of DNA vaccination against prostate carcinoma by boosting with recombinant protein vaccine and by introduction of a novel adjuvant epitope. Vaccine 27: 5411-5418.
22. Jin L, Zhu A, Wang Y, Chen Q, Xiong Q, et al. (2008) A Th1-recognized peptide P277, when tandemly repeated, enhances a Th2 immune response toward effective vaccines against autoimmune diabetes in nonobese diabetic mice. J Immunol 180: 58-63.
23. Hoang PT, Park P, Cobb LJ, Paharkova-Vatchkova V, Hakimi M, et al. (2010) The neurosurvival factor Humanin inhibits beta-cell apoptosis via signal transducer and activator of transcription 3 activation and delays and ameliorates diabetes in nonobese diabetic mice. Metabolism 59: 343-349.
24. Martin S, Hibino T, Faust A, Kleemann R, Kolb H (1996) Differential expression of ICAM-1 and LFA-1 versus L-selectin and VCAM-1 in autoimmune insulitis of NOD mice and association with both Th1- and Th2-type infiltrates. J Autoimmun 9: 637-643. (Pubitemid 26370974)
25. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63.
26. Zoka A, Muzes G, Somogyi A, Varga T, Szeman B, et al. (2013) Altered immune regulation in type 1 diabetes. Clin Dev Immunol 2013: 254874.
27. Bahey-El-Din M, Gahan CG (2011) Lactococcus lactis-based vaccines: current status and future perspectives. Hum Vaccin 7: 106-109.
28. Nouaille S, Ribeiro LA, Miyoshi A, Pontes D, Le Loir Y, et al. (2003) Heterologous protein production and delivery systems for Lactococcus lactis. Genet Mol Res 2: 102-111. (Pubitemid 38846553)
29. Steidler L (2003) Gene exchange of thyA for interleukin-10 secures live GMO bacterial therapeutics. Discov Med 3: 49-51.
30. Lei H, Xu Y, Chen J, Wei X, Lam DM (2010) Immunoprotection against influenza H5N1 virus by oral administration of enteric-coated recombinant Lactococcus lactis mini-capsules. Virology 407: 319-324.
31. Yam KK, Hugentobler F, Pouliot P, Stern AM, Lalande JD, et al. (2011) Generation and evaluation of A2-expressing Lactococcus lactis live vaccines against Leishmania donovani in BALB/c mice. J Med Microbiol 60: 1248-1260.
32. Xiong Q, Jin L, Li J, Fan H, Cao R, et al. (2009) A Th2 immune shift to heat shock protein 65 fails to arrest atherosclerosis: Proatherogenic role of Th2- deviated autoantibodies. Autoimmunity 42: 475-483.
33. Nitta Y, Tashiro F, Tokui M, Shimada A, Takei I, et al. (1998) Systemic delivery of interleukin 10 by intramuscular injection of expression plasmid DNA prevents autoimmune diabetes in nonobese diabetic mice. Hum Gene Ther 9: 1701-1707. (Pubitemid 28418740)
34. Prud'homme GJ, Chang Y (1999) Prevention of autoimmune diabetes by intramuscular gene therapy with a nonviral vector encoding an interferon-gamma receptor/IgG1 fusion protein. Gene Ther 6: 771-777.
35. Dieye Y, Usai S, Clier F, Gruss A, Piard JC (2001) Design of a protein-targeting system for lactic acid bacteria. J Bacteriol 183: 4157-4166. (Pubitemid 32568066)